CAR-T与阻断PD-1联合治疗在实体瘤中的研究进展

Progress in CAR-T Cell therapy Combined with PD-1 Blockade Therapy for Solid Tumors

近年来,嵌合抗原受体修饰T细胞(chimeric antigen receptor-modified T cells,CAR-T)在血液系统肿瘤中的临床疗效显著,但在实体瘤的治疗中面临诸多挑战。在实体肿瘤微环境中,CAR-T细胞表面高表达的程序性细胞死亡蛋白-1(programmed cell death-1,PD-1)是限制发挥疗效的主要因素。故而,阻断PD-1可以提高CAR-T细胞的效应功能,并显著降低肿瘤负荷。本文总结了CAR-T与PD-1阻断联合治疗在实体瘤中临床前及临床中的研究现状。

Recently,chimeric antigen receptor(CAR)-T cell therapy has made remarkable success in hematological malignancies but faces a series of challenges in solid tumors.One of the major problems is that CAR-T cells overexpress programmed death-1(PD-1)in tumor microenvironment.Therefore,blocking PD-1 can rescue the effector functions of CAR-T cells and reduce tumor burden significantly.Herein,it is aimed to summarize the progress in preclinical and clinical research on immunotherapy of combining CAR-T cells with PD-1 blockade for solid tumors.